New publication "What phases of the drug development framework can epidemiological studies emulate?" at Am J Epi led by me (!), with contributions from @ja_labrecque_, @BarWoolf, Emily, David R, and Sofia: https://t.co/w6E68ch4Q9
@stevesphd@BarWoolf@ERSpublications Really important work (and delighted to help) using pulmonary hypertension as a disease exemplar. Applicable across all rare disease I expect.
New manuscript led by @BarWoolf "A cautionary note on the naive use of general-population biobanks to study pulmonary arterial hypertension" is now published at Euro Respiratory Journal @ERSpublications: https://t.co/f67T79vQ5N. Summary follows:
One of my students @StEdmundsCam has a really remarkable story of overcoming adversity to study @Cambridge_Uni. Sadly his scholarship can't fund the rest of his degree so he is trying crowdfunding. Any help would be really appreciated, thank you very much! https://t.co/B3irpVstL3
New pre-print online: "Context-stratified Mendelian randomization: exploiting regional exposure variation to explore causal effect heterogeneity and non-linearity", https://t.co/1QssGzqrsB. We propose an alternative approach to assess non-linearity in Mendelian randomization.
New paper published at AJE Advances: "The role of estimation in Mendelian randomization: should Mendelian randomization investigations provide estimates?" led by @BarWoolf and myself. Brief thread:
Posting a tad late, but @jamesyrmsk and @dpsg108 and I have a new research letter in @intjepidemiol where we use negative controls to illustrate why drug use phenotypes should not be used as exposures in MR studies https://t.co/yIOJ8Ce9ya
🚨 New preprint awaiting feedback! 🚨 led by the lovely and talented @martaalcalde18 looking at the relationship between PDE5 inhibition and Alzheimer's disease using #mendelianrandomization (spolier: we found nada) https://t.co/jd1XETKNzw
Had a lot of fun presenting our work (accepted this week at the AJE) on exposure miss-identification in MR, and how it results in directionally incorrect conclusions for studies of caffeine consumption at #mrconf24.
Had a lot of fun presenting our work (accepted this week at the AJE) on exposure miss-identification in MR, and how it results in directionally incorrect conclusions for studies of caffeine consumption at #mrconf24.
Our new study https://t.co/28nuS6EJy9 with James Perry, Charles Hong @mark_toshner, @stevesphd, @dpsg108, Martin Wilkins, and Chris Rhodes failed to find evidence supporting the use of IL6R inhibitors on pulmonary arterial hypertension.
**Flash Talks Event** Benjamin Woolf @BarWoolf shares his research "Comparison of caffeine consumption behavior with plasma caffeine levels as exposure measures in drug-target Mendelian randomization studies" Vote for your favourite talk: https://t.co/SOqVzKV9Ww
New paper: "A frequentist test of proportional colocalization after selecting relevant genetic variants": https://t.co/v8EgM37Ouq led by Ash Patel. We introduce a new test for colocalization in a frequentist paradigm. Thread follows!
Our review "Incorporating biological and clinical insights into variant choice for Mendelian randomisation: examples and principles" written together with @htcronje and published at @eGastro_BMJ is now available at https://t.co/b6i9wnJgBJ. Brief thread: